Novartis Investigative Site

San Miguel, Lima region 32

0 studies enrolling now · 8 studies all time

What they study most

Breast Cancer, Cardiovascular Disease and Lipoprotein(a), Chronic Heart Failure With Reduced Ejection Fraction, Chronic Obstructive Pulmonary Disease, Cytokine Storm (Covid-19), Heart Failure With Preserved Ejection Fraction, Heart Failure With Reduced Ejection Fraction

Studies at this site

• Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD — Running, not enrolling
• Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer — Completed
• Lipoprotein(a) in Patients With Cardiovascular Disease (CVD) — Completed
• Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm — Completed
• A Randomized, Double-blind Controlled Study Comparing LCZ696 to Medical Therapy for Comorbidities in HFpEF Patients — Completed
• Safety and Tolerability During Open-label Treatment With LCZ696 in Patients With CHF and Reduced Ejection Fraction — Completed
• This Study Will Evaluate the Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality of Patients With Chronic Heart Failure — Stopped early
• Effect of QVA149 Versus NVA237 and Tiotropium on Chronic Obstructive Pulmonary Disorder (COPD) Exacerbations — Completed